Clinical Trial Update: A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN) [Phase 2]

View source ↗

Summary

A multicenter, single-arm Phase 2 trial evaluating AK112 in combination with chemotherapy as first-line treatment for patients with non-squamous non-small cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• AK112

Snippet

Sponsor: Sun Yat-sen University | Conditions: NSCLC, Brain Metastasases | Phase 2 | Status: NOT_YET_RECRUITING